Curious about the following: "In December 2012, data from a pilot Phase II clinical trial of Pracinostat in combination with Vidaza® (azacitidine) in patients with advanced myelodysplastic syndrome (MDS) were presented at the American Society of Hematology Annual Meeting. Data from nine patients treated at the MD Anderson Cancer Center showed an overall response rate (CR+CRi+PR) of 89%, including seven complete responses."
Namely, should we expect single-agent Vidaza to produce 7 CRs out of 9 patients in this patient population or is this HDAC truly adding a significant benefit here?
News 
Market Data 
Discover 
